Sentence examples for I responder from inspiring English sources

Clinically relevant criteria, such as the Outcomes Measures in Rheumatology Clinical Trials Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria, have been suggested for use in economic evaluations of treatments for OA.

All other efficacy variables assessed were exploratory, including the Outcome Measures in Rheumatoid Arthritis Clinical Trials – Osteoarthritis Research Society International (OMERACT-OARSI) responder variable [ 25] and use of rescue medications.

These analyses included the difference between the groups from baseline at week 26 in WOMAC A and the differences from baseline over and at 26 weeks in WOMAC A1, WOMAC subscale C, PGA, COGA, and the responders to treatment per the Outcome Measures in Rheumatology, Osteoarthritis Research Society International (OMERACT OARSI) responder criteria.

In addition, the percentage of subjects who responded favorably to the product (as measured by the OMERACT-OARSI responder rate) was higher in Hydros and Hydros-TA groups as compared to Synvisc-One.

Future testing will be required to better characterize the relationship between the IL-1ra IL-1β ratIL-1ra IL-1βentration, and OMERACT-OARSI responder status.

The subset of subjects whose IL-1ra IL-1β ratIL-1ra IL-1β0 in theiratio had a greater probability of being a OMERACT-OARSI responder than the total study population.

Chi-square tests were used to assess univariate associations between (i) responders and non-responders to the full questionnaire and (ii) characteristics of the participants and the primary and secondary outcomes.

It was surprisingly hard to collect public data for this study as we required trials of at least 20 human subjects with a defined clinical binary outcome, i.e. (i) responders and non-responders, (ii) at least some detectable difference in gene expression at baseline between the two groups and (iii) the availability of a similar but entirely independent trial for testing purposes.

At 1-year follow-up, 7 (54%) subjects were classified as CGI-I responders.

Median TTP was 38.0 months for 13/14 patients; median TTP was 27.0 months for Id responders (n = 4) compared with 45.0 months for Id non-responders (n = 9) (Supplementary Fig 2a; log-rank P value = 0.206).

The proportion of HAMA and CGI-I responders in the vilazodone 40-mg/day group was comparable to other antidepressants in the treatment of GAD.